| Title: | Impact of single-heterozygous UGT1A1 on the clinical outcomes of irinotecan monotherapy after fluoropyrimidine and platinum-based combination therapy for gastric cancer : a multicenter retrospective study |
| Authors: | Nakano, Shintaro Browse this author |
| Yuki, Satoshi Browse this author |
| Kawamoto, Yasuyuki Browse this author →KAKEN DB |
| Nakatsumi, Hiroshi Browse this author →KAKEN DB |
| Ando, Takayuki Browse this author |
| Kajiura, Shinya Browse this author →KAKEN DB |
| Yoshikawa, Ayumu Browse this author |
| Harada, Kazuaki Browse this author |
| Hatanaka, Kazuteru Browse this author |
| Tanimoto, Aya Browse this author |
| Ishiguro, Atsushi Browse this author |
| Honda, Takuya Browse this author |
| Dazai, Masayoshi Browse this author |
| Sasaki, Takahide Browse this author |
| Sakamoto, Naoya Browse this author →KAKEN DB |
| Komatsu, Yoshito Browse this author →KAKEN DB |
| Keywords: | Gastric cancer |
| Irinotecan |
| Issue Date: | Oct-2021 |
| Publisher: | Springer |
| Journal Title: | International journal of clinical oncology |
| Volume: | 25 |
| Start Page: | 1800 |
| End Page: | 1806 |
| Publisher DOI: | 10.1007/s10147-020-01720-y |
| Abstract: | Background It is unclear whether the UGT1A1 status, single heterozygous (SH) or wild type (WT), is associated with the efficacy and toxicity of irinotecan monotherapy in advanced gastric cancer (AGC). We investigated the association between clinical outcomes (efficacy and safety) and UGT1A1 status in patients who received irinotecan monotherapy. Methods We evaluated AGC patients who received irinotecan monotherapy between January 2011 and December 2017. Efficacy was assessed according to overall survival (OS) and progression-free survival (PFS). Toxicity was graded using the Common Toxicity Criteria for Adverse Events (version 4.0). Results A total of 100 patients were evaluated (62 and 38 patients with UGT1A1 WT and SH, respectively). In the WT and SH groups, the irinotecan dose was reduced in 19 (30.6%) and 18 (47.2%) patients (p = 0.135), respectively; treatment was delayed due to adverse events (AEs) in 19 (30.6%) and 13 (34.2%) patients (p = 0.826), respectively; the median PFS was 3.15 and 3.25 months (HR, 0.734; 95% CI 0.465-1.158;p = 0.184), respectively; and the median OS was 10.4 and 7.26 months (HR, 1.137; 95% CI 0.752-1.721;p = 0.543), respectively. Severe hematological AEs (Grade >= 3) were significantly more frequent in the SH group than in the WT group (63% vs. 36%;p = 0.008), while severe non-hematological AEs was not significantly different (16.0% vs. 6.5%;p = 0.173). Conclusion There was no significant difference in the efficacy of irinotecan monotherapy between UGT1A1 WT and UGT1A1 SH, but UGT1A1 SH was associated with a high frequency of severe hematological toxicity. |
| Rights: | http://creativecommons.org/licenses/by/4.0/ |
| Type: | article |
| URI: | http://hdl.handle.net/2115/79364 |
| Appears in Collections: | 北海道大学病院 (Hokkaido University Hospital) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
